Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis

Gernot Wagner; Gerald Gartlehner; Kylie Thaler; Dominic Ledinger; Johanna Feyertag; Irma Klerings; K M Saif-Ur-Rahman; Declan Devane; Kate Olsson; Karam Adel Ali; Sabine Vygen-Bonnet; Heini Salo; Dace Zavadska; Marta Grgič Vitek; Marje Oona; Robert Cunney; David Tuerlinckx; Frederikke Kristensen Lomholt; Isolde Sommer

doi:10.1038/s41541-024-01048-y

Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis

Gernot Wagner (Corresponding Author)
, Gerald Gartlehner
, Kylie Thaler
, Dominic Ledinger
, Johanna Feyertag
, Irma Klerings
, K M Saif-Ur-Rahman
, Declan Devane
, Kate Olsson
, Karam Adel Ali
, Sabine Vygen-Bonnet
, Heini Salo
, Dace Zavadska
, Marta Grgič Vitek
, Marje Oona
, Robert Cunney
, David Tuerlinckx
, Frederikke Kristensen Lomholt
, Isolde Sommer

Rīga Stradiņš University

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

6 Downloads (Pure)

Abstract

Pneumococcal infections are a serious health issue associated with increased morbidity and mortality. This systematic review evaluated the efficacy, effectiveness, immunogenicity, and safety of the pneumococcal conjugate vaccine (PCV)15 compared to other pneumococcal vaccines or no vaccination in children and adults. We identified 20 randomized controlled trials (RCTs). A meta-analysis of six RCTs in infants showed that PCV15 was non-inferior compared with PCV13 for 12 shared serotypes. Based on a meta-analysis of seven RCTs in adults, PCV15 was non-inferior to PCV13 for 13 shared serotypes. For the unique PCV15 serotypes, 22F and 33F, immune responses were higher in infants and adults vaccinated with PCV15 compared to those receiving PCV13. Regarding safety, meta-analyses indicated comparable risks of adverse events between PCV15 and PCV13 in infants. Adults receiving PCV15 had a slightly higher risk of adverse events, though serious events were similar between groups.

Original language	English
Article number	257
Journal	npj Vaccines
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41541-024-01048-y
Publication status	Published - 30 Dec 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1038/s41541-024-01048-yLicence: CC BY-NC-ND

Immunogenicity and safetyFinal published version, 1.39 MBLicence: CC BY-NC-ND

Cite this

Wagner, G., Gartlehner, G., Thaler, K., Ledinger, D., Feyertag, J., Klerings, I., Saif-Ur-Rahman, K. M., Devane, D., Olsson, K., Adel Ali, K., Vygen-Bonnet, S., Salo, H., Zavadska, D., Grgič Vitek, M., Oona, M., Cunney, R., Tuerlinckx, D., Kristensen Lomholt, F., & Sommer, I. (2024). Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis. npj Vaccines, 9(1), Article 257. https://doi.org/10.1038/s41541-024-01048-y

@article{10e247aeda0b43f38a4a65776db881c2,

title = "Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis",

abstract = "Pneumococcal infections are a serious health issue associated with increased morbidity and mortality. This systematic review evaluated the efficacy, effectiveness, immunogenicity, and safety of the pneumococcal conjugate vaccine (PCV)15 compared to other pneumococcal vaccines or no vaccination in children and adults. We identified 20 randomized controlled trials (RCTs). A meta-analysis of six RCTs in infants showed that PCV15 was non-inferior compared with PCV13 for 12 shared serotypes. Based on a meta-analysis of seven RCTs in adults, PCV15 was non-inferior to PCV13 for 13 shared serotypes. For the unique PCV15 serotypes, 22F and 33F, immune responses were higher in infants and adults vaccinated with PCV15 compared to those receiving PCV13. Regarding safety, meta-analyses indicated comparable risks of adverse events between PCV15 and PCV13 in infants. Adults receiving PCV15 had a slightly higher risk of adverse events, though serious events were similar between groups.",

author = "Gernot Wagner and Gerald Gartlehner and Kylie Thaler and Dominic Ledinger and Johanna Feyertag and Irma Klerings and Saif-Ur-Rahman, \{K M\} and Declan Devane and Kate Olsson and \{Adel Ali\}, Karam and Sabine Vygen-Bonnet and Heini Salo and Dace Zavadska and \{Grgi{\v c} Vitek\}, Marta and Marje Oona and Robert Cunney and David Tuerlinckx and \{Kristensen Lomholt\}, Frederikke and Isolde Sommer",

note = "{\textcopyright} 2024. The Author(s).",

year = "2024",

month = dec,

day = "30",

doi = "10.1038/s41541-024-01048-y",

language = "English",

volume = "9",

journal = "npj Vaccines",

issn = "2059-0105",

publisher = "Nature Research",

number = "1",

}

Wagner, G, Gartlehner, G, Thaler, K, Ledinger, D, Feyertag, J, Klerings, I, Saif-Ur-Rahman, KM, Devane, D, Olsson, K, Adel Ali, K, Vygen-Bonnet, S, Salo, H, Zavadska, D, Grgič Vitek, M, Oona, M, Cunney, R, Tuerlinckx, D, Kristensen Lomholt, F & Sommer, I 2024, 'Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis', npj Vaccines, vol. 9, no. 1, 257. https://doi.org/10.1038/s41541-024-01048-y

TY - JOUR

T1 - Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis

AU - Wagner, Gernot

AU - Gartlehner, Gerald

AU - Thaler, Kylie

AU - Ledinger, Dominic

AU - Feyertag, Johanna

AU - Klerings, Irma

AU - Saif-Ur-Rahman, K M

AU - Devane, Declan

AU - Olsson, Kate

AU - Adel Ali, Karam

AU - Vygen-Bonnet, Sabine

AU - Salo, Heini

AU - Zavadska, Dace

AU - Grgič Vitek, Marta

AU - Oona, Marje

AU - Cunney, Robert

AU - Tuerlinckx, David

AU - Kristensen Lomholt, Frederikke

AU - Sommer, Isolde

PY - 2024/12/30

Y1 - 2024/12/30

N2 - Pneumococcal infections are a serious health issue associated with increased morbidity and mortality. This systematic review evaluated the efficacy, effectiveness, immunogenicity, and safety of the pneumococcal conjugate vaccine (PCV)15 compared to other pneumococcal vaccines or no vaccination in children and adults. We identified 20 randomized controlled trials (RCTs). A meta-analysis of six RCTs in infants showed that PCV15 was non-inferior compared with PCV13 for 12 shared serotypes. Based on a meta-analysis of seven RCTs in adults, PCV15 was non-inferior to PCV13 for 13 shared serotypes. For the unique PCV15 serotypes, 22F and 33F, immune responses were higher in infants and adults vaccinated with PCV15 compared to those receiving PCV13. Regarding safety, meta-analyses indicated comparable risks of adverse events between PCV15 and PCV13 in infants. Adults receiving PCV15 had a slightly higher risk of adverse events, though serious events were similar between groups.

AB - Pneumococcal infections are a serious health issue associated with increased morbidity and mortality. This systematic review evaluated the efficacy, effectiveness, immunogenicity, and safety of the pneumococcal conjugate vaccine (PCV)15 compared to other pneumococcal vaccines or no vaccination in children and adults. We identified 20 randomized controlled trials (RCTs). A meta-analysis of six RCTs in infants showed that PCV15 was non-inferior compared with PCV13 for 12 shared serotypes. Based on a meta-analysis of seven RCTs in adults, PCV15 was non-inferior to PCV13 for 13 shared serotypes. For the unique PCV15 serotypes, 22F and 33F, immune responses were higher in infants and adults vaccinated with PCV15 compared to those receiving PCV13. Regarding safety, meta-analyses indicated comparable risks of adverse events between PCV15 and PCV13 in infants. Adults receiving PCV15 had a slightly higher risk of adverse events, though serious events were similar between groups.

UR - https://www.scopus.com/pages/publications/85213694839

U2 - 10.1038/s41541-024-01048-y

DO - 10.1038/s41541-024-01048-y

M3 - Article

C2 - 39738219

SN - 2059-0105

VL - 9

JO - npj Vaccines

JF - npj Vaccines

IS - 1

M1 - 257

ER -

Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis

Abstract

UN SDGs

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this